Form 4: Fulgent Genetics CEO Ming Hsieh Reports Stock Transaction
SEC Form 4 Filing
Fulgent Genetics CEO Ming Hsieh reports disposition of shares to cover tax obligations and details beneficial ownership through various trusts and custodial accounts.
Summary
- On February 1, 2025, Ming Hsieh, CEO of Fulgent Genetics, disposed of 1,472 shares of common stock to satisfy tax withholding obligations related to vesting restricted stock units.
- The transaction price was $16.64 per share.
- Following the transaction, Hsieh directly owns 702,239 shares.
- Hsieh also indirectly owns 220,816 shares through the Dynasty Trust, 7,895,115 shares through The Ming Hsieh Trust, and 1,000 shares each in two Uniform Transfers to Minors Act accounts.
- Hsieh disclaims beneficial ownership of the Dynasty Trust shares except for any pecuniary interest.
- Hsieh has sole voting and dispositive power over the shares held by The Ming Hsieh Trust and the Uniform Transfers to Minors Act accounts.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document reports a routine transaction related to tax obligations. It doesn't indicate any significant positive or negative developments for the company.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard transaction to cover tax obligations related to vested stock units, which is a common practice among executives.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/01/2022 | Date of restricted stock units grant to the reporting person. |
| 08/03/2022 | Date Form 4 filed with the U.S. Securities and Exchange Commission reporting the restricted stock units grant. |
| 02/01/2025 | Date of the stock transaction (disposal of shares). |
| 02/04/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Stock Transaction, Ming Hsieh, Fulgent Genetics, FLGT, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.